TARS vs. LEGN, GRFS, TGTX, NUVL, LNTH, TLX, AXSM, CRSP, ADMA, and PCVX
Should you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), ADMA Biologics (ADMA), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.
Tarsus Pharmaceuticals vs. Its Competitors
Legend Biotech (NASDAQ:LEGN) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.
Legend Biotech has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.
In the previous week, Legend Biotech had 9 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 11 mentions for Legend Biotech and 2 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.13 beat Legend Biotech's score of 0.41 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.
Legend Biotech currently has a consensus price target of $72.60, indicating a potential upside of 93.65%. Tarsus Pharmaceuticals has a consensus price target of $66.67, indicating a potential upside of 67.97%. Given Legend Biotech's higher possible upside, research analysts clearly believe Legend Biotech is more favorable than Tarsus Pharmaceuticals.
70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Legend Biotech has a net margin of -29.95% compared to Tarsus Pharmaceuticals' net margin of -44.91%. Legend Biotech's return on equity of -21.19% beat Tarsus Pharmaceuticals' return on equity.
Tarsus Pharmaceuticals has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Legend Biotech beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Tarsus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tarsus Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:TARS) was last updated on 7/9/2025 by MarketBeat.com Staff
